EU approves Scanis mammography system
Software designed to automatically locate and highlight subtle abnormalities is part of a computer-aided mammography system that recently gained European marketing approval.The Mammex TR is a computer-aided diagnosis system intended to help
Software designed to automatically locate and highlight subtle abnormalities is part of a computer-aided mammography system that recently gained European marketing approval.
The Mammex TR is a computer-aided diagnosis system intended to help radiologists improve their accuracy in evaluating mammograms. The Foster City, CA, company did much of the early development and testing of the technology with the University of California, San Francisco, and Stanford University.
According to Scanis, proprietary rule-based algorithms and filters identify and classify small and obscure features of diagnostic interest. In other words, the software is designed to find subtle abnormalities the radiologist may have missed. It works by digitizing film mammograms and displaying them on a monitor so the radiologist can compare them to the original.
Now that the Mammex TR has obtained the CE Mark under the European Union's Medical Device Directive, Scanis will be starting the FDA premarket approval process in the next few months, according to company spokesperson Bob Chapman. A Canadian application is expected to be approved shortly, he said.
"We have a close relationship with the University of Southern California, which is developing a protocol," Chapman said. "and we will be working with several more institutions."
Possible Real-Time Adaptive Approach to Breast MRI Suggests ‘New Era’ of AI-Directed MRI
June 3rd 2025Assessing the simulated use of AI-generated suspicion scores for determining whether one should continue with full MRI or shift to an abbreviated MRI, the authors of a new study noted comparable sensitivity, specificity, and positive predictive value for biopsies between the MRI approaches.
Can AI Assessment of PET Imaging Predict Treatment Outcomes for Patients with Lymphoma?
June 2nd 2025The use of adjunctive AI software with pre-treatment PET imaging demonstrated over a fourfold higher likelihood of predicting progression-free survival (PFS) in patients being treated for lymphoma, according to a new meta-analysis.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
